LivaNova PLC (NASDAQ:LIVN) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,887 shares of the company’s stock after selling 895 shares during the quarter. Jackson Creek Investment Advisors LLC owned about 0.05% of LivaNova worth $1,338,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Point72 Asset Management L.P. boosted its stake in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares during the period. Geode Capital Management LLC boosted its position in LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after buying an additional 8,331 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after acquiring an additional 133,401 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after acquiring an additional 93,311 shares during the last quarter. Finally, Paradice Investment Management LLC lifted its stake in shares of LivaNova by 15.3% in the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company’s stock worth $22,545,000 after acquiring an additional 64,680 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Needham & Company LLC lowered their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Barclays decreased their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday. Mizuho cut their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.17.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.27% of the company’s stock.

LivaNova Stock Down 2.1 %

LIVN stock opened at $39.17 on Friday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 93.26 and a beta of 1.10. LivaNova PLC has a 1-year low of $38.91 and a 1-year high of $64.47. The firm has a fifty day moving average price of $46.79 and a two-hundred day moving average price of $49.32. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.